Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Megaveti | Pharma | 32.7% | 80th pct | 110 |
| Inparm | Pharma | 13.6% | 47th pct | 110 |
| Denk Pharma Caucasus | Pharma | 10.7% | 40th pct | 110 |
| New Georgia - 555 | Pharma | 6.6% | 28th pct | 110 |
| Sama Holding | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Line item | Inparm | New Georgia - 555 | Denk Pharma Caucasus | Megaveti | Sama Holding |
|---|---|---|---|---|---|
| Total Current Assets | 7,210 | 3,129 | 12,415 | 0 | — |
| Total Non-Current Assets | 13 | 6,066 | 735 | 9,955 | — |
| TOTAL ASSETS | 7,223 | 9,195 | 13,150 | 9,955 | — |
| Total Current Liabilities | 14,901 | 743 | 8,520 | 1,532 | — |
| Total Non-Current Liabilities | 0 | 904 | 0 | 0 | — |
| TOTAL LIABILITIES | 14,901 | 1,647 | 8,520 | 1,532 | — |
| Total Equity | -7,678 | 7,548 | 4,630 | 8,423 | — |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | — |
| Total Debt | 0 | 1,008 | 3 | 0 | — |
| Cash & Equivalents | 689 | 1,050 | 2,098 | 2,233 | — |
| Net Debt | -689 | -42 | -2,095 | -2,233 | — |
Not every picked company reports every selected year — FY2024: no filing for Sama Holding. Those cells are left blank (no filing), not zero.